Abraxis BioScience (ABII)

Amortization of Intangible Assets

Amortization of intangibles assets totaled $39.8 million, $39.4 million and $38.6 million for the years ended December 31, 2009, 2008 and 2007, respectively, and included $31.5 million in each of the years for amortization associated with the U.S. rights to Abraxane^®. The increase in 2008 amortization of intangible assets from 2007 relates to incremental amortization associated with the acquisition of Shimoda Biotech and Platco Technologies in April 2008.

Amortization of Intangible Assets

Amortization of intangible assets for the three months ended March 31, 2009 was $9.9 million compared to $9.7 million for the same period in the prior year.

Amortization of Intangible Assets

Amortization of intangibles assets totaled $39.4 million, $38.6 million and $27.3 million for the years ended December 31, 2008 2007 and 2006, respectively, and included $31.5 million in each of 2008 and 2007 and $22.2 million in 2006 of amortization associated with the U.S. rights to Abraxane^®. The increase in 2008 amortization of intangible assets from 2007 relates to incremental amortization associated with the acquisition of Shimoda Biotech and Platco Technologies in April 2008 and the increase in the 2007 amortization from 2006 relates to the fact that 2006 did not include a full year of amortization associated with the U.S. rights to Abraxane.

Amortization of Intangible Assets

Amortization of intangibles assets totaled $39.4 million, $38.6 million and
$27.3 million for the years ended December 31, 2008 2007 and 2006, respectively, and included $31.5 million in each of 2008 and 2007 and $22.2 million in 2006 of amortization associated with the U.S. rights to AbraxaneFACE="Times New Roman" SIZE="1">^®. The increase in 2008 amortization of intangible assets from 2007 relates to incremental amortization associated with the acquisition of Shimoda Biotech and Platco Technologies in April 2008
and the increase in the 2007 amortization from 2006 relates to the fact that 2006 did not include a full year of amortization associated with the U.S. rights to Abraxane.

FACE="Times New Roman" SIZE="2">Acquired in-Process Research and Development

In connection with the purchase of Shimoda
Biotech and Platco Technologies in April 2008, we acquired certain research and development projects that were required to be expensed in accordance with generally accepted accounting principles. Approximately $13.9 million of the purchase price was
expensed as in-process research and development for projects that, as of the acquisition date, had not yet reached technological or regulatory feasibility and had no alternative future uses in their current states.